Form 8-K - Current report:
SEC Accession No. 0001213900-24-085116
Filing Date
2024-10-03
Accepted
2024-10-03 17:25:23
Documents
14
Period of Report
2024-09-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0216077-8k_nkgen.htm   iXBRL 8-K 29022
  Complete submission text file 0001213900-24-085116.txt   246453

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nkgn-20240928.xsd EX-101.SCH 3742
3 XBRL DEFINITION FILE nkgn-20240928_def.xml EX-101.DEF 26569
4 XBRL LABEL FILE nkgn-20240928_lab.xml EX-101.LAB 36569
5 XBRL PRESENTATION FILE nkgn-20240928_pre.xml EX-101.PRE 25193
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0216077-8k_nkgen_htm.xml XML 5651
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 241352705
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)